RxDoctor Payments Data

Cristina Tamasdan, MD

Pain Medicine · Bridgeport, CTNPI 1134329436

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pain medicine clinicians in CT, where the typical reported total is $2,061.

$938in general payments, 2019–2025

Across 19 payments — averaging $49.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$183
  • Medtronic$166
  • Sirtex Medical Inc$157
  • Nalu Medical, Inc.$68
  • Pacira Pharmaceuticals Incorporated$50
  • Bioventus LLC$44
  • plus $269 from 9 others

What the payments were for

  • Travel & lodging$718%
  • Food & beverage$86792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 30th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$89,550
Medicare patients
243
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate16$5,449
Fentanyl36$2,996
Pregabalin146$2,323
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$1,800
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen106$1,798
Oxycodone Hcl88$1,211
Methocarbamol63$713
Hydromorphone Hcl37$386
Gabapentin34$371
Tizanidine Hcl13$262
Methadone Hcl12$246
Baclofen11$206
Morphine Sulfate13$194
Duloxetine Hcl17$165
Tramadol Hcl23$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$20$5,44916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 69 pain medicine providers in Connecticut.

Other pain medicine in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →